[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475618":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"ART Fertility Clinics LLC","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Natural Cycle Protocol",null,"Ultrasound monitoring to monitor follicular and endometrial growth. Serial measurements of serum Lutenizing Hormone (LH), estradiol (E2), and progesterone (P4) to identify ovulation.\n\nMinimal endometrial thickness of 7 mm is required. No progesterone supplementation. Embryo transfer (ET) will be scheduled 5 days after the day of ovulation (120 hours of P4 exposure).\n\nBlood samples will be drawn to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 on day of ovulation (P4 rise), on the day before ET, on the day of ET and 3 and 10 days later, between 9 and 12 am.\n\nA blood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +\u002F- 3 days in case of pregnancy, between 9 and 12 am.\n\nIn case of pregnancy, a blood test to measure PIBF, IL-17, IFγ, IL-10, IL-4 and TGF-ß1 will be performed at 5 weeks +\u002F- 3 days between 9 and 12 am..",{"label":13,"type":10,"description":14,"interventionNames":15},"Hormone Replacement Therapy Protocol","Ultrasound monitoring of endometrial growth and exclude growing follicle\n\nOral Estradiol Valerate (Progyluton) 4 mg on cycle day 2 at 7 pm for 2 days. On 3rd day, increase dose to 6 mg. The dose may be increased based on endometrial thickness.\n\nOnce endometrial thickness is at least 7 mm and trilaminar, after 10-15 days of Estradiol Valerate administration, start Endometrin 100 mg at 1 pm and 9 pm. From 2nd day onwards increase to 3 times daily. Continue Progyluton \\& Endometrin until 12 weeks of pregnancy\n\nET on the 5th full day of Endometrin administration\n\nBlood test to measure PIBF, IL-17, IFγ, IL-4, IL-10 and TGF-ß1 on the 1st day of Endometrin supplementation (before 1st administration), on the 4th day of Endometrin administration, on the day of ET and 3 and10 days after, 4 to 7 hours after the morning administration.\n\nBlood test to measure beta human chorionic gonadotropin (ß-hCG) will be performed 3 and 10 days after ET and at 5 weeks +\u002F- 3 days if pregnancy.",[16,17],"Drug: Endometrin 100Mg Vaginal Insert","Drug: Estradiol Valerate",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Endometrin 100Mg Vaginal Insert","Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm",[13],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Estradiol Valerate","Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).",[13],[29],{"name":30,"affiliation":5,"role":31},"LAURA MARQUETA MARQUES, Consultant","PRINCIPAL_INVESTIGATOR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"BARBARA LAWRENZ, PhD","CONTACT","97126528000","1108","barbara.lawrenz@artfertilityclinics.com",{"name":40,"role":35,"phone":36,"phoneExt":10,"email":41},"SUZAN SAMIR","suzan.samir@artfertilityclinics.com",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Abu Dhabi","Abu Dhabi Emirate","60202","United Arab Emirates","AE",{"type":51,"coordinates":52},"Point",[53,54],54.39696,24.45118,{"lat":54,"lon":53},[57,60],{"name":58,"role":35,"phone":59,"phoneExt":10,"email":41},"Barbara Lawrenz, PhD","+97102 652 8000",{"name":61,"role":31,"phone":10,"phoneExt":10,"email":10},"Laura Marqueta Marques",{"type":31,"investigatorFullName":61,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal Investigator","100475618","descriptive-analysis-of-serum-immunological-markers-during-an-euploid-frozen-embryo-transfer-in-a-natural-cycle-100475618",false,"NCT05473273","Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle.","Descriptive Analysis of Serum Immunological Markers During an Euploid Frozen Embryo Transfer in a Natural Cycle (NC).","Inclusion Criteria:\n\n* Women aged 18 years to 40 years\n* Having at least one good quality (grade A or B for inner mass cell and trophectoderm) day 5 or 6 chromosomally normal cryopreserved blastocyst available for transfer\n* Single embryo transfer in a natural cycle (NC) or an Hormone Replacement Therapy (HRT) protocol\n* Fresh ejaculate used for fertilization\n\nExclusion Criteria:\n\n* Body mass index lower than 18.5 or equal or higher than 29 kg\u002Fm2\n* Endometriosis or adenomyosis suspected by medical history (dysmenorrhea, dyspareunia, heavy or prolonged menstrual bleeding (\\> 8 days), chronic pelvic pain, catamenial rectal or bladder symptoms) or diagnosed by imaging (magnetic resonance imaging or ultrasonography)\n* Uterine abnormalities\n* Hydrosalpinx\n* Insulin resistance or diabetes mellitus diagnosed by HbA1c 5.7 %\n* Antiphospholipid syndrome\n* Polycystic ovarian syndrome according to Rotterdam criteria: presence of at least two of the following: irregular cycles (\\\u003C 21 or \\> 35 days or \\\u003C 8 cycles a year), biochemical or clinical hyperandrogenism, ovarian ultrasound morphology (\\> 20 follicles per ovary on transvaginal scan) or Anti-mullerian hormone \\> 5,98 ng\u002Fml\n* History of recurrent miscarriage, defined as the loss of 2 or more pregnancies according to ESHRE guidelines\n* History of implantation failure, considered as the lack of pregnancy after the transfer of 2 good-quality (grade A or B for inner mass cell and trophectoderm (29)) euploid embryos\n* History or suspicion of Asherman syndrome\n* Autoimmune disease\n* Couple first degree consanguineous",true,"FEMALE","18 Years","40 Years",{"count":76,"type":77},40,"ESTIMATED","OBSERVATIONAL","To describe the peripheral serum levels of the anti-inflammatory cytokines IL-4 (Interleukin-4), IL-10 (Interleukin-10), TGF-ß1 (Transforming Growth Factor beta1), the pro-inflammatory cytokines IL-17 (Interleukin-17), IFγ (Interferon Gamma) and the immune mediator PIBF (Progesterone-Induced Blocking Factor) along a single frozen euploid blastocyst transfer in a natural cycle (NC) or Hormone Replacement Therapy (HRT).",[81],"Infertility, Female",[83,84,85,86,87,88,89,90],"infertilty","ivf","progesterone","estradiol","cytokines","immunology","Pharmacological effect of drugs","hormones","2026-06-22",{"date":93,"type":94},"2026-06-25","ACTUAL",{"date":96,"type":94},"2023-04-24",{"date":98,"type":77},"2026-12-30",{"name":5,"class":6},1]